Zyla Life Sciences Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 17 rows in 2016. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2016-12-20: Reporting owner CARLIN BARBARA; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-12-12: Reporting owner Radie Robert S; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-12-06: Reporting owner VARKI PAUL; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-12-06: Reporting owner Shea Patrick M; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2016-12-20 | CARLIN BARBARA Officer (Chief Accounting Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,500 28,500 owned after | $8.62 exercise price | 2016-12-20 | |
| 2016-12-12 | Radie Robert S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $8.13 exercise price | 2016-12-13 | |
| 2016-12-06 | VARKI PAUL Officer (SVP, GC & Chief Compliance Off) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $8.11 exercise price | 2016-12-08 | |
| 2016-12-06 | Shea Patrick M Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $8.11 exercise price | 2016-12-08 | |
| 2016-12-06 | Dayno Jeffrey M. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $8.11 exercise price | 2016-12-08 | |
| 2016-12-06 | Strobeck Mark Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $8.11 exercise price | 2016-12-08 | |
| 2016-12-06 | Musial Stan Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $8.11 exercise price | 2016-12-08 | |
| 2016-12-06 | Radie Robert S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $8.11 exercise price | 2016-12-08 | |
| 2016-10-03 | Shea Patrick M Officer (Chief Commercial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +127,500 127,500 owned after | $7.55 exercise price | 2016-10-04 | |
| 2016-06-22 holding as of filing | VARKI PAUL Officer (SVP, GC & Chief Compliance Off) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $10.63 exercise price | 2016-06-22 | ||
| 2016-06-15 | NICOLAIDES NICHOLAS C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,666 29,666 owned after | $4.98 exercise price | 2016-07-22 | |
| 2016-06-15 | OSBORN JOHN E Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,666 29,666 owned after | $4.98 exercise price | 2016-07-22 | |
| 2016-06-15 | Walbert Timothy P Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,666 29,666 owned after | $4.98 | 2016-06-17 | |
| 2016-01-11 holding as of filing | CARLIN BARBARA Officer (Chief Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $13.04 exercise price | 2016-01-11 | ||
| 2016-01-11 holding as of filing | CARLIN BARBARA Officer (Chief Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.33 exercise price | 2016-01-11 | ||
| 2016-01-04 | LINDHARDT KARSTEN Officer (VP, Research & Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $10.98 | 2016-07-06 | |
| 2016-01-04 | CARLIN BARBARA Officer (Chief Accounting Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,500 17,500 owned after | $10.98 exercise price | 2016-01-11 |